Director, HTA, Value & Evidence, Specialty Care (GI)

The Director, HTA, Value & Evidence, Specialty Care (GI) at Pfizer is responsible for developing and executing strategies that generate evidence supporting access to our medicines. This includes overseeing the evidence generation strategy for etrasimod (VELSIPITY), leading real-world data studies, and collaborating with cross-functional teams to create a comprehensive approach to value and evidence that meets the needs of diverse stakeholders.

To qualify for the Director, HTA, Value & Evidence, Specialty Care (GI) position at Pfizer, candidates must have a graduate degree (MSc, MPH, or PhD) and significant experience in health economics and outcomes research (HEOR). Ideal candidates will demonstrate expertise in health services research methods, collaboration in a matrix environment, and the ability to manage multiple complex projects autonomously.

In the role of Director, HTA, Value & Evidence, Specialty Care (GI) at Pfizer, you will lead various high-impact studies, including real-world evidence generation studies focused on treatment patterns, real-world effectiveness, and burden of illness. Additionally, you will execute studies that are aligned with the global HEOR strategy, which cater to interests of payers, patients, and healthcare providers.

Pfizer is committed to supporting the professional development of its employees, including the Director, HTA, Value & Evidence. The company provides resources for continuous learning, opportunities to work on innovative projects across various therapeutic areas, and a collaborative environment where leadership skills can be further developed.

The work environment for the Director, HTA, Value & Evidence, Specialty Care (GI) at Pfizer is dynamic and collaborative. This hybrid position allows for flexibility while requiring you to work on-site 2 to 3 days a week. You'll embolden strategic discussions with diverse teams and engage directly with stakeholders, fostering a culture of innovation and impact.

As the Director of HTA, Value & Evidence, I would develop multi-faceted access strategies that leverage real-world evidence and stakeholder collaboration to demonstrate the economic and clinical value of our medications. I would ensure that our evidence generation aligns closely with payer needs and health technology assessment requirements.

I have developed health economic models that assess cost-effectiveness and budget impacts for various treatment options. My approach involves leveraging robust data sources to inform models, ensuring they reflect real-world scenarios to provide evidence to payers of our treatments’ value.

Prioritizing projects requires a clear understanding of business objectives and stakeholder needs. I would regularly assess project urgency and impact, utilizing feedback from cross-functional teams to align resources effectively, ensuring that crucial projects receive appropriate attention and execution aligns with Pfizer's strategic goals.

Teamwork is essential in my approach as a Director. I believe in fostering an inclusive environment where team members’ ideas are valued. I actively engage with cross-functional teams to harness diverse perspectives, which enhances the comprehensive strategies for evidence generation and ultimately benefits patient outcomes.

I led a challenging project focused on building a real-world evidence study for a newly launched product. We faced tight timelines and resource constraints, but by implementing agile project management techniques and fostering close communication with stakeholders, we successfully delivered actionable insights, reinforcing the importance of adaptability and collaborative efforts.

To stay informed about trends in health technology assessments, I subscribe to industry journals, attend relevant conferences, and participate in webinars. Networking with peers and thought leaders also provides insights into emerging methodologies and best practices, which I apply to my strategies at Pfizer.

I have provided oversight on numerous real-world evidence studies, focusing on patient-reported outcomes and treatment patterns. This experience has equipped me to design studies that answer crucial questions about our therapies in routine practice, allowing us to substantiate claims of effectiveness and value to payers.

I would address this skepticism by presenting robust evidence from real-world studies that highlight the product's effectiveness in improving patient outcomes. Additionally, I would engage in discussions to understand their concerns thoroughly and be prepared to pivot our narrative based on their feedback to demonstrate the product’s clinical and economic benefits distinctly.

I utilize various tools and methodologies for economic evaluations, including Markov models, regression analysis, and cost-utility analysis. By employing these techniques and combining quantitative and qualitative data, I can present a comprehensive assessment that resonates with both stakeholders and decision-makers.

Ensuring compliance with Pfizer's SOPs starts with thorough planning and familiarization with relevant protocols. I implement regular reviews and communication with my team to reinforce compliance at every stage of a project, leveraging audit trails and documentation practices to maintain transparency and accountability.